Dr. Bouchard is an intellectual property lawyer and scholar, specializing in innovation, regulation and litigation of biomedical products. His career has focused on the science, law, policy, regulation and commercialization of innovative medical technologies. He started as a medical scientist, completing a PhD and Postdoctoral Fellowship in the field of ion channel biophysics and Ca2+ imaging. He shifted focus to obtain a law degree specializing in pharmaceutical and biotechnology law and has since been involved in the prosecution, acquisition, financing, distribution and litigation of intellectual property rights. Dr. Bouchard has appeared before the Federal Court of Canada and the Supreme Court of Canada. He has consulted with firms, universities, governments and international organizations on legal, regulatory and policy issues. He worked with the Government of Canada on its emerging platforms for lifecycle-based drug approval and public private partnerships in technology commercialization. His research has been funded by federal and provincial funding agencies and private endowments. Dr. Bouchard’s scholarly expertise is focused on intellectual property and regulatory aspects of therapeutic product development, including global aspects of technology commercialization, patenting, licensing and regulatory approval, and empirical assessment of the impact of government stimulus packages and regulation on technology innovation.
Law and Technology
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
Qualifying Intellectual Property II: A Novel Innovation Index for Pharmaceutical Products, Santa Clara Computer and High Technology Law Journal (2012)
Governments around the world are increasingly engaged with the political mandate of innovation, which is...
Canada’s laws on pharmaceutical intellectual property: The case for fundamental reform (with Paul Grootendorst and Aidan Hollis), Canadian Medical Association Journal (2011)
Society supports drug R&D by granting drug companies patents and other forms of intellectual property...
Structure-Function Analysis of Global Pharmaceutical Linkage Regulations, Minnesota Journal of Law, Science & Technology (2011)
Prompt and affordable access to essential medicines is a component of almost all domestic and...
Science and Technology
Qualifying Intellectual Property II: A Novel Innovation Index for Pharmaceutical Products, Santa Clara Computer and High Technology Law Journal (2012)
Governments around the world are increasingly engaged with the political mandate of innovation, which is...
Empirical analysis of drug approval-patenting linkage for high value pharmaceuticals, Northwestern Journal of Technology & Intellectual Property (2010)
Global drug regulators have long privileged models of therapeutic product development that provide strong intellectual...
Empirical analysis of drug approval data 2001-2008: Are Canadian pharmaceutical players “doing more with less”?, McGill Journal of Law & Health (2009)
Canada’s proposed new drug regime, termed the “Progressive Licensing Framework” (PLF), has received consid-erable attention...
The Mud and the Blood and the Beer: Canada’s new Progressive Licensing Framework for drug approval, McGill Journal of Law & Health (2009)
Canada is currently undergoing a transition in its system of public health, including major redefinition...
The Pas de Deux of Pharmaceutical Regulation and Innovation: Who’s Leading Whom?, Berkeley Technology Law Journal (2009)
Global drug development is undergoing a redefinition of the responsibilities of those who develop, regulate,...
Intellectual Property Law
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
Qualifying Intellectual Property II: A Novel Innovation Index for Pharmaceutical Products, Santa Clara Computer and High Technology Law Journal (2012)
Governments around the world are increasingly engaged with the political mandate of innovation, which is...
Canada’s laws on pharmaceutical intellectual property: The case for fundamental reform (with Paul Grootendorst and Aidan Hollis), Canadian Medical Association Journal (2011)
Society supports drug R&D by granting drug companies patents and other forms of intellectual property...
Structure-Function Analysis of Global Pharmaceutical Linkage Regulations, Minnesota Journal of Law, Science & Technology (2011)
Prompt and affordable access to essential medicines is a component of almost all domestic and...
Medical Jurisprudence
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
Empirical analysis of drug approval-patenting linkage for high value pharmaceuticals, Northwestern Journal of Technology & Intellectual Property (2010)
Global drug regulators have long privileged models of therapeutic product development that provide strong intellectual...
Empirical analysis of drug approval data 2001-2008: Are Canadian pharmaceutical players “doing more with less”?, McGill Journal of Law & Health (2009)
Canada’s proposed new drug regime, termed the “Progressive Licensing Framework” (PLF), has received consid-erable attention...
The Mud and the Blood and the Beer: Canada’s new Progressive Licensing Framework for drug approval, McGill Journal of Law & Health (2009)
Canada is currently undergoing a transition in its system of public health, including major redefinition...
Health Law and Policy
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
Qualifying Intellectual Property II: A Novel Innovation Index for Pharmaceutical Products, Santa Clara Computer and High Technology Law Journal (2012)
Governments around the world are increasingly engaged with the political mandate of innovation, which is...
Canada’s laws on pharmaceutical intellectual property: The case for fundamental reform (with Paul Grootendorst and Aidan Hollis), Canadian Medical Association Journal (2011)
Society supports drug R&D by granting drug companies patents and other forms of intellectual property...
Structure-Function Analysis of Global Pharmaceutical Linkage Regulations, Minnesota Journal of Law, Science & Technology (2011)
Prompt and affordable access to essential medicines is a component of almost all domestic and...
Food and Drug Law
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
Qualifying Intellectual Property II: A Novel Innovation Index for Pharmaceutical Products, Santa Clara Computer and High Technology Law Journal (2012)
Governments around the world are increasingly engaged with the political mandate of innovation, which is...
Canada’s laws on pharmaceutical intellectual property: The case for fundamental reform (with Paul Grootendorst and Aidan Hollis), Canadian Medical Association Journal (2011)
Society supports drug R&D by granting drug companies patents and other forms of intellectual property...
Structure-Function Analysis of Global Pharmaceutical Linkage Regulations, Minnesota Journal of Law, Science & Technology (2011)
Prompt and affordable access to essential medicines is a component of almost all domestic and...
Public Law and Legal Theory
Qualifying Intellectual Property I: Harmonized Measurement of New and Follow-On Drug Approvals, Patents and Chemical Components, Boston University Journal of Science and Technology Law (2012)
The purpose of this study was to develop a harmonized method to collect, compare and...
I’m Still Your Baby: Canada’s Continuing Support of U.S. Linkage Regulations for Pharmaceuticals, Marquette Intellectual Property Review (2011)
Canada’s linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in...
Law and Society
Canada’s laws on pharmaceutical intellectual property: The case for fundamental reform (with Paul Grootendorst and Aidan Hollis), Canadian Medical Association Journal (2011)
Society supports drug R&D by granting drug companies patents and other forms of intellectual property...
I’m Still Your Baby: Canada’s Continuing Support of U.S. Linkage Regulations for Pharmaceuticals, Marquette Intellectual Property Review (2011)
Canada’s linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in...
Privatizing Biomedical Research- A ‘Third Way’, Nature Biotechnology (2008)
The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed...
No subject area
I'm Still Your Baby: Canada's Continuing Support of U.S. Linkage Regulations for Pharmaceuticals, Intellectual Property Law Review (2011)
Canada's linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in...